Genitourinary syndrome of menopause (GSM) affects up to 80% of postmenopausal women, manifesting as a range of vulvovaginal symptoms that can severely impact quality of life, sexual health and overall well-being. Despite its prevalence, GSM and its associated symptoms are often underdiagnosed and undertreated. This program aims to bridge the knowledge gap by providing healthcare providers with a comprehensive understanding of the hormonal influences on vulvovaginal health and practical guidance on managing vulvovaginal symptoms through both non-hormonal and hormonal therapies, including new therapeutic options. By the end of this program, participants will be equipped with the tools necessary to improve patient outcomes through timely recognition and appropriate intervention.
This program has received financial support from Lupin Pharma Canada in the form of an unrestricted educational grant.
